Phlow

Phlow is pioneering bold solutions that restore pharmaceutical sovereignty to the United States. We are honored to have been selected to participate in the FDA Commissioner’s National Priority Voucher (CNPV) pilot program. This critical initiative will accelerate our efforts to establish a fully domestic, end-to-end supply chain for ketamine, spanning from raw materials to finished dosage form, thereby closing a vital gap in national health security and further strengthening resilience in the U.S. supply chain.    Watch the recent Bloomberg segment highlighting the FDA’s National Priority Voucher initiative and Phlow’s role in shaping the future of how medicines are made in America.    #Phlow #FDA #Essentialmedicines #Americanmade #Pharmaceuticalsovereignty

We’re honored to announce that Phlow Corp. has been selected as the ketamine sponsor in the U.S. Food and Drug Administration (FDA) Commissioner’s first-ever National Priority Voucher (CNPV) pilot program. This designation recognizes Phlow’s leadership in advancing U.S.-based manufacturing of essential medicines.   The FDA’s CNPV Pilot Program is designed to accelerate the development and regulatory review of projects that address a U.S. public health crisis, strengthen the U.S. pharmaceutical supply chain, and reduce dependence on foreign manufacturing. Earlier this year, Phlow proposed ketamine, a critical medicine widely used as a general anesthetic in both civilian and military medicine settings, for inclusion in the CNPV Pilot Program.   With no current domestic ketamine API suppliers, Phlow’s project, in partnership with the U.S. Department of Health and Human Services (HHS) HHS Administration for Strategic Preparedness and Response (ASPR), is intended to establish a fully domestic, end-to-end supply chain, from raw materials to finished dosage form, closing a vital gap in national health security. As part of the pilot, Phlow will leverage the voucher to accelerate FDA review timelines, ensuring the timely and resilient availability of this essential medicine through secure U.S.-based production.   Our Nation has suffered from multi-year ketamine shortages, with a notable shortage lasting from February 2018 to August 2025. By advancing U.S.-based API production, Phlow is helping to ensure a more secure, transparent, and reliable supply of this critical medicine while reducing the Nation’s dependence on overseas sources. Read the FDA press release: https://lnkd.in/e7QsK3Aj Read Phlow's press release: https://lnkd.in/eTM9J45j

At Phlow, we believe that strengthening America’s medicine supply chain is a shared responsibility and one of the most meaningful ways we can serve public health and national security.   Our new video highlights how strategic stockpiling and domestic API manufacturing can help solve one of the most pressing challenges of our time: overdependence on foreign sources for the essential ingredients in our medicines.   SAPIR, the Strategic Active Pharmaceutical Ingredient Reserve, is Phlow’s forward-looking model to address this challenge. It secures critical pharmaceutical ingredients, reduces reliance on vulnerable global supply chains, and supports a more responsive, elevated approach to public health preparedness.   This is not just a supply chain solution. It is a strategic investment in national resilience. Watch to learn more about Phlow's work: https://lnkd.in/e9MPzS2V   We are honored to work in partnership with federal agencies and leaders across healthcare and biopharma to help ensure essential medicines are available when and where they are needed most.

Phlow is pleased to announce the appointment of Tim M. Mayleben as Chairman of our Board of Directors. A trusted advisor, Tim brings more than 25 years of leadership in the biopharmaceutical industry and a proven ability to scale organizations that unite purpose with performance. His appointment marks an exciting new chapter as we continue accelerating our mission to create the future of how medicines are made and reclaim America’s pharmaceutical sovereignty. With Tim’s guidance and our dedicated board, Phlow will continue building the modern infrastructure and innovation needed to strengthen U.S. pharmaceutical development and manufacturing for generations to come. Read the full press release: https://lnkd.in/eE6Rk4MN #PhlowCorp #PharmaManufacturing #Leadership #USManufacturing #CDMO

Phlow is headed to CPHI Frankfurt 2025, taking place from October 28th to 30th at Messe Frankfurt in Germany. As a U.S.-based CDMO built for modern pharmaceutical development and manufacturing, we’re excited to connect with pharma and biopharma leaders from around the globe. With advanced development capabilities, both continuous and batch manufacturing, and purpose-built infrastructure in the United States, Phlow offers a reliable and agile path from early development through commercial scale-up. At a time when quality, speed, and supply chain resilience are more critical than ever, Phlow represents a new kind of partner: technically deep, operationally flexible, and fully domestic. Our Business Development team will be attending the conference in Frankfurt. To explore U.S.-based solutions for your next program, connect directly with David Young or Simon Hickling here on LinkedIn to schedule a meeting. #CPHIFrankfurt #PharmaManufacturing #CDMO #USManufacturing #Phlow

Tomorrow marks the start of the Contract Pharma 2025 Contracting & Outsourcing Conference in New Brunswick, NJ, and Phlow will be there. Our Business Development team is looking forward to connecting with pharmaceutical and biopharmaceutical leaders to discuss how Phlow’s U.S.-based CDMO services are transforming the way medicines are developed and manufactured in America. With state-of-the-art facilities at our Petersburg, VA, campus and Richmond, VA, laboratories, Phlow provides solutions for small molecule API development and manufacturing, from route design and process optimization to kilo-scale and metric ton-scale production. By harnessing advanced technologies such as continuous flow chemistry, we help our partners accelerate speed to market, reduce waste, and strengthen supply chain resilience. If you are attending #ContractPharma tomorrow, we’d welcome the opportunity to meet and discuss how Phlow can support your development and manufacturing needs. #CDMO #PharmaceuticalManufacturing #Innovation #Phlow

Phlow is hiring individuals who share our commitment to strengthening America’s medicine supply chain and making a lasting impact for the next generation. Join a team that’s advancing the future of how medicines are made in America through innovation and purpose-driven work. Environmental Affairs Coordinator Location: Petersburg, VA In this role, you will help lead environmental compliance and regulatory programs in support of pharmaceutical R&D and operations. Key focus areas include hazardous waste (RCRA), air permitting, industrial wastewater and stormwater management, aboveground/underground storage tanks, and regulatory data reporting. This position ensures compliance with local, state, and federal environmental regulations and will work closely with cross-functional teams, external business partners, and regulatory agencies. View Role and Apply: https://lnkd.in/esgrRbUa Government Program Finance Senior Analyst Location: Richmond, VA or Remote (U.S.-based) This individual will be responsible for supporting all financial aspects of Phlow’s government contracts, including budgeting, forecasting, financial reporting, and compliance. The role will work cross-functionally with our Finance and Contract teams to ensure effective, efficient practices and full adherence to applicable regulations, including the Federal Acquisition Regulation (FAR) and Cost Accounting Standards (CAS). This is a critical role supporting the operational success and integrity of Phlow’s government-funded programs. View Role and Apply: https://lnkd.in/eCfzWhkr Explore additional openings: View All Careers at Phlow: https://lnkd.in/evz95_2t #NowHiring #RemoteJobs #PurposeDrivenWork #Phlow

Today, Governor Glenn Youngkin announced that Eli Lilly and Company will move forward with plans for a $5 billion state-of-the-art manufacturing facility in Goochland County, Virginia. As a trailblazing B Corporation proudly based in nearby City of Richmond, Virginia and City of Petersburg, VA, we congratulate and applaud Eli Lilly and all those involved in further positioning the Commonwealth of Virginia as a cornerstone of America’s domestic pharmaceutical supply chain, producing both critical drug components and finished medicines. This announcement underscores the collective work of a region, and a Nation, committed to American jobs, American ingenuity, and American manufacturing. Congratulations to all involved as we work together to reclaim our Nation’s pharmaceutical sovereignty. Read more here: https://lnkd.in/e6YNJUvW

We’re proud to congratulate Phlow's CEO and Chairman, Eric Edwards, MD, PhD, on being named to the Virginia Business 2025–26 Virginia 500 Power List. Each year, the Virginia 500 Power List highlights the Commonwealth’s most influential leaders across business, healthcare, government, and education. Eric’s recognition reflects his leadership in reshaping how medicines are made in America and strengthening Virginia’s innovation ecosystem. We also congratulate other outstanding regional leaders honored this year. Together, these leaders are shaping a stronger, healthier, more resilient future for Virginia and beyond. Read the full list: Virginia 500: 2025–26 Power List: https://lnkd.in/eaKRFGaE

Today, Phlow observes the 5th annual National Essential Medicine Shortage Awareness Day and reaffirms our commitment to strengthening America’s medicine supply chain and building a more resilient future. Read our full corporate statement here: https://lnkd.in/ecsMXr8S #NEMSAD #StopTheShortages #Phlow